- Part B: ED SCLC with ongoing clinical benefit (stable disease [SD], partial response [PR], or complete response [CR]) following no more than 4 cycles of first-line platinum-based chemotherapy with the last dose of chemotherapy ≥ 28 days prior to the study day 1 (first-line consolidation setting).